靶向CD19的CAR-T细胞疗法用于弥漫性系统性硬化症患者:病例系列
在德国埃尔朗根大学医院连续招募6例对至少两种治疗反应不足的严重弥漫性系统性硬化症患者,接受靶向CD19的CAR-T细胞治疗(每公斤体重1×10^6个CAR-T细胞)。中位随访487天,观察期内无事件发生;6个月时ACR-CRISS评分改善概率中位达100%,mRSS中位下降31%(8分),CT示病变范围中位减少4%,FVC中位改善195 mL。
要点
- 6例严重弥漫性系统性硬化症患者接受靶向CD19的CAR-T细胞治疗,观察期内无预设事件发生。
- 6个月时ACR-CRISS评分改善概率中位达100%,mRSS中位下降31%(8分)。
- CT示病变范围中位减少4%,FVC中位改善195 mL。
核心结论
- 作者提供首个证据表明靶向CD19的CAR-T细胞疗法可能干预系统性硬化症患者纤维化器官表现的进展。
研究设计与样本
- 病例系列,在德国埃尔朗根大学医院内科3部连续招募6例对至少两种治疗反应不足的严重弥漫性系统性硬化症患者,接受靶向CD19的CAR-T细胞治疗(每公斤体重1×10^6个CAR-T细胞)。
- 主要结局为入组后无事件时间或治疗强化;关键次要结局包括mRSS、影像学、实验室检查、患者报告结局及改良版ACR-CRISS,在基线、3、6、9、12个月评估。
主要发现
- 2022年4月20日至2023年11月8日招募6例患者(中位年龄42岁[IQR 36-53];4男2女;均为白人欧洲裔),中位随访487天(IQR 342-585),观察期内无事件发生。
- ACR-CRISS评分改善概率在6个月时中位增至100%(IQR 100-100)。
- mRSS中位下降31%(IQR 29-38),对应100天内中位下降8分(IQR 7-13)。
- CT扫描病变范围中位减少4%(IQR 3-4),归因于磨玻璃影减少而网状模式保持稳定。
- FVC在最新观察时间点中位改善195 mL(IQR 18-275)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has shown remarkable outcomes in patients with systemic lupus erythematosus. The effects of CD19-targeting CAR T cells on organ manifestations in patients with systemic sclerosis have yet to be characterised. B cells have a central role in the pathogenesis of systemic sclerosis. We present a detailed analysis of the effects of CD19-targeting CAR T-cell therapy in patients with systemic sclerosis. METHODS: Six patients with severe diffuse systemic sclerosis with an insufficient response to at least two treatments were consecutively recruited at the Department of Internal Medicine 3, University Hospital Erlangen (Erlangen, Germany) to receive CD19-targeting CAR T-cell treatment (1 × 106 CAR T cells per kg bodyweight). Events were predefined by progression of interstitial lung disease, onset of congestive heart failure, onset of renal failure, onset of arterial hypertension, or initiation of new immunosuppressive or antifibrotic therapy. Event-free time or treatment intensification after study entry was the primary outcome. Key secondary outcomes included changes in the modified Rodnan Skin Score (mRSS), imaging (a component of the assessment of lung fibrosis), laboratory assessments, patient-reported outcomes, and a modified version of the American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS), assessed at baseline, 3 months, 6 months, 9 months, and 12 months. FINDINGS: Between April 20, 2022, and Nov 8, 2023, six patients with severe diffuse systemic sclerosis (median age 42 years [IQR 36-53]; four men and two women; all White European) were recruited and received CD19-targeted CAR T-cell therapy. The median follow-up time was 487 days (IQR 342-585). No events occurred within the observational period. Probability of improvement in the ACR-CRISS score increased to a median of 100% (IQR 100-100) at 6 months. Median mRSS decreased by 31% (IQR 29-38), corresponding to a median of 8 points (IQR 7-13) within 100 days. The extent of disease on CT scan decreased by a median of 4% (IQR 3-4) due to reduction of ground-glass opacities while the reticular pattern remained stable. Forced vital capacity improved by a median of 195 mL (IQR 18-275) at the latest observational timepoint. INTERPRETATION: We provide the first evidence that CD19-targeting CAR T-cell therapy might intercept with the progression of fibrotic organ manifestations in patients with systemic sclerosis. FUNDING: Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, ELAN-Foundation Erlangen, IZKF Erlangen, and Bundesministerium für Bildung und Forschung.
引用
- Auth J, Müller F, Völkl S, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. 2024. PMID: 39542003. doi:10.1016/S2665-9913(24)00282-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。